Patient info Open main menu

Rebif 44 micrograms / 0.5 ml solution for injection in cartridge – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine strength:
44 micrograms / 0.5 ml
Contains active substance:
Similar medicines:

Patient leaflet - Rebif 44 micrograms / 0.5 ml solution for injection in cartridge

1. What Rebif is and what it is used for 2. What you need to know before you use Rebif 3. How to use Rebif

Other medicines and Rebif

Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.

  1. 4.

    Possible side effects

    • Before the injection, use an alcohol wipe to

In particular you should tell your doctor if you are using antiepileptics or antidepressants.

  1. 5.

    How to store Rebif

    clean the skin at the injection site. Let the skin dry. If a bit of alcohol is left on the skin, you may get a stinging sensation.

  2. 6.

    Contents of the pack and other information

    Pregnancy and breast-feeding

  3. 1.

    What Rebif is and what it is used for

    If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

    How to inject Rebif

Rebif belongs to a class of medicines known as interferons. These are natural substances that transmit messages between cells. Interferons are produced by the body and play an essential role in the immune system. Through mechanisms that are not totally understood, interferons help to limit the damage of the central nervous system associated with multiple sclerosis.

  • Your doctor will tell you how to choose the

    correct dose of 44 micrograms. Please read also the instructions in the manual provided with your device (RebiSmart).

No harmful effects on the breastfed newborn/ infant are anticipated. Rebif can be used during breast-feeding.

RebiSmart

Driving and using machines

  • Please ensure that the dose displayed on the screen

Effects of the disease itself or of its treatment might influence your ability to drive or to use machines. You should discuss this with your doctor if you are concerned.

of the device corresponds to the prescribed dose of 44 micrograms before the injection.

Rebif is a highly purified soluble protein that is similar to the natural interferon beta that is produced in the human body.

  • Place RebiSmart at a right angle (90°) to the

    skin.

Rebif is used for the treatment of multiple sclerosis. It has been shown to reduce the number and the severity of relapses and to slow the progression of disability. It is also approved for use in patients who have experienced a single clinical event likely to be a first sign of multiple sclerosis.

Rebif contains sodium and benzyl alcohol

  • Press the injection button. During the injection, the

    button will flash.

This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free’.

  • Wait until the light switches off. This tells you

    that the injection is completed.

  • Remove RebiSmart from the injection site.

This medicine contains 2.5 mg benzyl alcohol per dose. Benzyl alcohol may cause allergic reactions. Benzyl alcohol has been linked with the risk of severe side effects including breathing problems (called “gasping syndrome”) in young children.

After the injection of Rebif with RebiSmart

2. What you need to know before you use Rebif

  • Remove and discard the needle according to the

    instruction manual provided with your device.

Do not use Rebif

  • Gently massage the injection site with a dry

Do not use for more than a week in young children (less than 3 years old), unless advised by your doctor or pharmacist.

  • if you are allergic to natural or recombinant

    cotton ball or gauze.

    interferon beta or any of the other ingredients of this medicine (listed in section 6). • if you are severely depressed at present or are

Ask your doctor or pharmacist for advice if you are pregnant or breast-feeding, or if you have a liver or kidney disease. This is because large amounts of benzyl alcohol can build-up in your body and may cause side effects (called “metabolic acidosis”).

developing thoughts of suicide.

If you have any further questions, please ask your doctor, nurse or pharmacist.

Warnings and precautions

Talk to your doctor, pharmacist or nurse before using Rebif.

If you use more Rebif than you should

In case of overdose, contact your doctor immediately.

3. How to use Rebif

  • Rebif should only be used under the supervision

    of your doctor.

    This medicine is for multidose use.

    If you forget to use Rebif

  • Before treatment with Rebif, read carefully

    Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.

    and follow the advice given under “How to use Rebif” in order to minimise the risk of injection site necrosis (skin breakdown and tissue destruction) that has been reported in patients treated with Rebif. If you experience troubling local reactions, contact your doctor. • Talk to your doctor or pharmacist before taking

    If you miss a dose, continue to inject from the day of the next scheduled dose. Do not use a double dose to make up for a forgotten dose.

    Dose

    Patients who have experienced a single clinical event

    If you stop using Rebif

    The usual dose is 44 micrograms (12 million IU) given three times per week.

    The effects of Rebif may not be noticed immediately. Therefore you should not stop using Rebif but continue to use it regularly to achieve the desired result. If you are uncertain about the benefits, please consult your doctor.

    Patients with multiple sclerosis

    Rebif if you have an allergy (hypersensitivity) to any other medicines.

    The usual dose is 44 micrograms (12 million IU) given three times per week. A lower dose of 22 micrograms (6 million IU) given three times per week is recommended for patients who cannot tolerate the higher dose.

  • Blood clots in the small blood vessels may occur

    during your treatment. These blood clots could affect your kidneys. This might happen several weeks to several years after starting Rebif. Your doctor may want to check your blood pressure, blood (platelet count) and the function of your kidney.

    You should not discontinue the treatment without first contacting your doctor.

    If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

    Rebif should be administered three times per week, and if possible:

    • on the same three days every week (at least

Inform your doctor if you have a disease of - the bone marrow,

4. Possible side effects

48 hours apart, e.g., Monday, Wednesday, Friday)

  • at the same time of day (preferably in the

    evening).

  • kidney,

    Tell your doctor immediately and stop using Rebif if you experience any of the following serious side effects:

    • Serious allergic (hypersensitivity) reactions. If, immediately following Rebif administration you experience a sudden difficulty breathing, which may appear in association with swelling of face, lips, tongue or throat, nettle rash, itching all over the body, and a feeling of weakness or faintness, contact your doctor immediately or seek urgent medical attention.

      These reactions are rare (may affect up to 1 in 1,000 people).

    • Inform your doctor immediately if you experience any of the following possible symptoms of a liver problem: jaundice (yellowing of the skin or of the whites of the eyes), widespread itching, loss of appetite accompanied by nausea and vomiting and easy bruising of the skin. Severe liver problems can be associated with additional signs, e.g. difficulty concentrating, sleepiness and confusion.
    • Depression is common (may affect up to 1 in

      10 people) in treated patients with multiple sclerosis. If you feel depressed or develop thoughts of suicide, report it immediately to your doctor.

Talk to your doctor if you experience any of the following side effects:

  • Flu-like symptoms, such as headache, fever, chills, muscle and joint pains, fatigue and nausea are very common (may affect more than 1 in 10 people).

    These symptoms are usually mild, are more common at the start of the treatment and decrease with continued use.

    To help reduce these symptoms your doctor may advise you to take a fever reducing painkiller before a dose of Rebif and then for 24 hours after each injection.

  • Injection site reactions including redness, swelling, discoloration, inflammation, pain and skin breakdown are very common.

    The occurrence of injection site reactions usually decreases over time.

    Tissue destruction (necrosis), abscess and mass at injection site are uncommon (may affect up to 1 in 100 people).

    See recommendations in section “Warnings and precautions” to minimise the risk of injection site reactions.

    The injection site can become infected (uncommon); the skin may become swollen tender and hard and the whole area could be very painful. If you experience any of these symptoms, contact your doctor for advice. • Certain laboratory tests may change. These changes are generally not noticed by the patient (no symptoms), are usually reversible and mild, and most often do not require particular treatment. The number of red blood cells, white blood cells or platelets may decrease either individually (very common) or all at one time (rare). Possible symptoms resulting from these changes could include tiredness, reduced ability to fight infection, bruising or unexplained bleeding. Liver function tests may be disturbed (very common). Inflammation of the liver has also been reported (uncommon). If you experience symptoms suggesting a liver disorder, such as loss of appetite accompanied by other symptoms such as nausea, vomiting, jaundice, please contact your doctor immediately (see above “Tell your doctor immediately...”). • Thyroid dysfunction is uncommon. The thyroid gland may function either excessively, or insufficiently. These changes in the thyroid activity are almost always not felt by the patient as symptoms; however your doctor may recommend testing as appropriate.

  • MS pseudo-relapse (frequency not known):

    There is a possibility that at the beginning of your treatment with Rebif you may experience symptoms that resemble those of a multiple sclerosis relapse. For example, your muscles may feel very tense or very weak, preventing you from moving as you want. In some cases such symptoms are associated with fever or flu-like symptoms described above. If you notice any of these side effects talk to your doctor.

Other possible side effects include:

Very common (may affect more than 1 in 10 people): • Headache

Common (may affect up to 1 in 10 people): • Insomnia (sleeping difficulty)

  • Diarrhoea, nausea, vomiting
  • Itching, rash (skin eruptions)
  • Muscle and joints pain
  • Fatigue, fever, chills
  • Hair loss

Uncommon (may affect up to 1 in 100 people): • Hives

  • Epileptic seizures
  • Liver inflammation (hepatitis)
  • Breathing difficulties
  • Blood clots such as deep venous thrombosis • Disorders of the retina (back of the eye) such as inflammation or blood clots with consequent vision disorders (vision disturbances, loss of vision)
  • Increased sweating
Info-Table - Version 03
IDENTIFICATION OF THE COMPONENT
N67R0202U
Local brand:REBIF
Strength(s):44 mcg/0.5 ml
TECHNICAL DATA
Packaging site:Merck Bari
Technical layout ref:SL03_V04
BARCODE
2D Code (DMC)
Alpha numeric content:N67R0202U
Spotmark:No
Spotmark value:n/a
TRACEABILITY (VERSIONS)
VxDateDesigner
0125.02.2024
02n/an/a
03n/an/a

TW4815876 N67R0202U Rare (may affect up to 1 in 1,000 people): • Suicide attempt

Marketing Authorisation Holder

Merck Serono Ltd. 5 New Square, Bedfont Lakes Business Park, Feltham, Middlesex, TW14 8HA

  • Serious skin reactions - some with mucosal lesions • Blood clots in the small blood vessels

    Manufacturer that can affect your kidneys (thrombotic thrombocytopenic purpura or haemolytic uremic syndrome). Symptoms may include increased bruising, bleeding, fever, extreme weakness, headache, dizziness or light-headedness. Your doctor may find changes in your blood and the function of your kidneys.

    Merck Serono S.p.A.

    Via delle Magnolie 15

    I-70026 Modugno (Bari)

    Italy

    This leaflet was last revised in 02/2025

  • Drug-induced lupus erythematosus: a side-effect of long-term use of Rebif. Symptoms may include muscle pain, joint pain and swelling, and rash. You may also experience other signs such as fever, weight loss, and fatigue. Usually symptoms disappear within one or two weeks after treatment is stopped.
  • Kidney problems including scarring that may reduce your kidney function.

    If you get some or all of these symptoms: - foamy urine

    • fatigue
    • swelling, particularly in the ankles and eyelids, and weight gain.

Tell your doctor as they may be signs of a possible kidney problem.

The following side effects were reported for interferon beta (frequency not known) • Dizziness

  • Nervousness
  • Loss of appetite
  • Dilatation of the blood vessels and palpitation • Irregularities and/or changes in menstrual flow • Pulmonary arterial hypertension - a disease of severe narrowing of the blood vessels in the lungs resulting in high blood pressure in the blood vessels that carry blood from the heart to the lungs. Pulmonary arterial hypertension has been seen at various time points during treatment, including several years after starting treatment with Rebif.
  • Inflammation of the fatty tissue under the skin

    (panniculitis), which can make the skin feel hard and possibly develop painful red lumps or patches. You should not stop or alter the medication without your doctor’s advice.

Children and teenagers

Side effects in children and teenagers are similar to those observed in adults.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via:

United Kingdom

Yellow Card Scheme

Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Rebif

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label after EXP.

Store in a refrigerator (2°C – 8°C).

Do not freeze. (To prevent accidental freezing, avoid placing near the freezer compartment). After first injection use within 28 days. The device (RebiSmart) containing a pre-filled cartridge of Rebif must be stored in the device storage box in a refrigerator (2°C - 8°C). For the purpose of ambulatory use, you may remove Rebif from the refrigerator and store it not above 25°C for one single period of up to 14 days. Rebif must then be returned to the refrigerator and used before the expiry date. Store in the original package in order to protect from light.

Do not use this medicine if you notice any visible signs of deterioration such as if the solution is no longer clear or if it contains particles.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away of medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Rebif contains

  • The active substance is interferon beta-1a.

    Each cartridge contains 132 micrograms corresponding to 36 million International Units (IU) of interferon beta-1a.

  • The other ingredients are mannitol, poloxamer 188, L-methionine, benzyl alcohol, sodium acetate, acetic acid, sodium hydroxide and water for injections.

What Rebif looks like and contents of the pack

Pre-filled cartridge (type 1 glass) with a plunger stopper (rubber) and a crimp cap (aluminium and halobutyl rubber), containing 1.5 mL solution for injection. Pack size of 4 or 12 cartridges. Not all pack sizes may be marketed.

The cartridge is to be used with the RebiSmart electronic injection device. The device is provided separately.

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PLGB 11648/0284

Last revision stated in the text: February 2025 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Rebif 44 micrograms / 0.5 ml solution for injection in cartridge

Active substance Interferon beta-1a
Strength 44 micrograms / 0.5 ml
Pharmaceutical form Clear to opalescent solution, with pH 3.7 to 4.1 and osmolarity 250 to 450 mOsm/L.
Excipients Mannitol, Poloxamer 188, L-methionine, Benzyl alcohol, Sodium acetate, Acetic acid for pH adjustment, Sodium hydroxide for pH adjustment, Water for injections
Shelf life 18 months.
Storage Store in a refrigerator (2°C – 8°C) away from the cooling element. Do not freeze. Store in the original package in order to protect from light.
For the purpose of ambulatory use, the patient may remove Rebif from the refrigerator and store it not above 25°C for one single period of up to 14 days. Rebif must then be returned to the refrigerator and used before the expiry date.
Drug group (ATC) Immunostimulants, Interferons
  1. L Antineoplastic and immunomodulating agents
    1. L03 Immunostimulants
      1. L03A Immunostimulants
        1. L03AB Interferons
          1. L03AB07 interferon beta-1a
Marketing authorisation PLGB 11648/0284 (first authorised 1 January 2021)
Marketing authorisation holder Merck Serono Limited

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.2.0 of 19 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.